chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Numbness in hands and shoulders; Shoulder blade, in the joints and muscles in deltoid or whatever that muscle is down to the forearm to like the first finger and thumb feel numb, like pricked by needles; Feels like arm is about to fall asleep from shoulder down to thumb; This is a spontaneous report from a contactable consumer (patient). A 56-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EW0161), via an unspecified route of administration, on 06May2021 at 18:00 (at the age of 56-year-old), as dose 1, single, in left arm for COVID-19 immunization at Pharmacy/drug store. The patient's medical history included diagnosed allergies, compromised immune status, respiratory illness, genetic/chromosomal abnormalities, endocrine abnormalities including diabetes and obesity and allergy to latex or IV needle/butterfly needle plastic material that caused his hands to swell up. The patient's past medications included Bupropion, Simvastatin, Metoprolol, and Xarelto; all taken for unspecified indications. Concomitant medications were not reported. Patient did not receive other shots on the same day of COVID vaccine, or 4 weeks prior. He experienced no problems with shots in the past. On 07May2021, 6 hours after the first dose of vaccine, the patient experienced numbness in hands and shoulders and shoulder blade, in the joints and muscles in deltoid or whatever that muscle was down to the forearm to like the first finger and thumb felt numb, like pricked by needles. On an unspecified date in May2021, after the first dose of vaccine, the patient felt like his arm was about to fall asleep from shoulder down to thumb. The patient was concerned that if this could be a heart condition or something else. The clinical outcome of all the events was not resolved.  Follow up attempts needed. Further information is expected.  Follow-up attempts completed. No further information expected.
7/7/04: mom called complained of left arm swollen from shoulder to elbow with redness and warmth per RN. 7/13/04: mom called, took child to see doctor on Friday 7/9/04 wt increased edema down to the wrist and was bluish-red. Mom states doctor said the arm was hard and felt the arm would have bruising and he felt when the shot was given it hit a vein. It arm not better by 7/12/04 , they were to return. Mom states child never complained of pain, no fever per RN. Pt recovered quickly.
Swelling reported to left upper arm, red "whelps" left upper arm; reported to health department after school the day following vaccinations.
Extreme fatigue for more than a week, stiff aching muscles for a week, tingling and weakness in legs for more than a week, light headedness for more than a week. No treatment other than Tylenol on occasion.
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 16-MAR-2016 the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 (lot # L040178, expiration date 18-AUG-2017). This specified lot number vaccine was exposed to temperature excursion two times. The total cumulative excursion time of the first time was 136 hours with the lowest recorded temperature of 33 Fahrenheit degree. The total cumulative excursion time of the second time was 40 hours with the lowest recorded temperature of 34 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse event was reported. This is one of several reports received from the same source. Additional information has been requested.
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose 12/30/21Lot#EL0142 2nd dose01/22/21 ,lot#EL3247 Diagnosed covid positive:08/13/21 Symptom onset:08/12/21 Exposure:Home Symptoms:fever, fatigue,muscle aches,congestion.
pt recv vax;exp inc resp rate&seen by MD;appeared to be in shock;maculopapular rash;to hosp;lab showed dec platelets&pneumonia;vesicles found to be varicella zoster;was fluid resuscitated&tx  w/ atbs;culture of trachea pos;resp fail
Full body pain, 24 hours Cycles of fever and chills, 60 hours Headache, 72 hours  all treated with Motrin with no observable benefit
Nausea, pooping, swollen eyes, etching hand / feet, aches, fatigue.
Employyee c/o of itchy throat within 15 minutes of vaccine administration. Employee was observed a total of 45 minutes. After 45 minutes, states throat itchiness is gone. No other symptoms noted. Vital signs = BP 141/86, HR= 72, Puls Ox = 99%
Soreness in the left arm lasting from 09-DEC-2001 and still unresolved on 21-DEC-2001.
This spontaneous report as received from a physician refers to a female patient of unknown age. On an unknown date the patient was vaccinated with ZOSTAVAX (lot# was not reported,Standard dose). On an unknown date the patient experienced mild rash on her breast after receiving ZOSTAVAX. The patient sought unspecified medical attention. The outcome of mild rash on her breast was unknown. This the 3rd patient from the building that had developed a rash after receiving the ZOSTAVAX vaccine. The other events had been reported previously. Additional information is not expected.
Headache within 1 hour Aches and pains within 8 hours Chills and fever Vertigo Nausea Dehydration Temp 99.7 Pain at injection site & arm within 10 hours No acetaminophen, anti-inflammatories, pain medication as per directions of UCI vaccine administrators.  All symptoms gone without medication within 24 hours
On 8/18/00, mother reported welt at injection site of chickenpox and itching.
Entire deltoid area of left arm began to feel hot swollen and itchy greater than 2 hours after the injection. Patient presented back to office w/normal vitals and no resp. sx. Localized heat and swelling w/spreading wheal appearance was verified applied ice/gave 50 mg oral BENADRYL and 400 mg Ibuprofen w/good response. Tried to call, unable to reach; was improved when left office.
Patient was fine for the day and evening of the vaccine. The next morning when she woke up, her arm below the injection site had a rash about 2 inches x 4 inches but was not itching. Two days post vaccine, the area is itching and getting larger. Patient will be following up with her medical doctor.
Patient experienced increased eye sensitivity to light, ataxia and grogginess after receiving the vaccine. His symptoms slowly dissipated over the course of the next week. On 10/13/16 patient stated that he had fully recovered from all adverse effects of the vaccine. I did not ask him at what time his symptoms started.
This spontaneous report was received from a physician via company representative referring to a 20 year old male patient. The patient's concurrent conditions, medical history, drug reactions/allergies and concomitant medication were unknown. Approximately in July 2016 (also reported as "4 months ago"), the patient was vaccinated with the first dose of GARDASIL 9 (Lot number and expiration date were not provided) 0.5 ml, intramuscular. After the patient received the vaccination (approximately in July 2016) he experienced a vasovagal syncope response. The patient did not seek for medical attention. The outcome of vasovagal syncope was reported as recovered/resolved on an unspecified date in 2016. The reporter did not assess the causal relationship between the adverse event and the vaccination with GARDASIL 9. Additional information has been requested.
Patient developed generalized urticaria, itching, and abdominal discomfort.  Patient presented to an emergency room and was treated with antihistamines.  Urticaria subsided after two to three weeks.  Patient then developed food allergy symptoms.  She now often has intermittent eruption of hives after a meal.
This spontaneous report as received from an office manager refers to a patient of unknown age. The patient was vaccinated with the first, second and third dose of hepatitis B vaccine (manufacturer unknown) (strength, dosage, route unknown) on 20-SEP-2008, 04-DEC-2008, 12-FEB-2009 respectively. The office manager emphasized RECOMBIVAX HB could not be ruled out. No adverse effects reported. Additional information has been requested.
22jan90 pt vax hepta B.  pt ex general weakness. 28dfeb90 pt vax 2nd hepta B. w/i 24hrs pt ex. pain and swelling at inject site, stomach cramps, joint pain, fever, gen weakness, diarrhea, and h/a. seen by physician and treated for sx.
A little achiness in fingers; I had a headache all night/it was pretty bad all night/it's much less now, but slightly there; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (A little achiness in fingers) and HEADACHE (I had a headache all night/it was pretty bad all night/it's much less now, but slightly there) in an 83-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 067F21A, 025A21A and 030L20A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included OMEPRAZOLE for Acid indigestion, SIMVASTATIN for an unknown indication.   On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 29-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 29-Nov-2021, the patient experienced PAIN IN EXTREMITY (A little achiness in fingers) and HEADACHE (I had a headache all night/it was pretty bad all night/it's much less now, but slightly there). At the time of the report, PAIN IN EXTREMITY (A little achiness in fingers) and HEADACHE (I had a headache all night/it was pretty bad all night/it's much less now, but slightly there) was resolving.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment details were reported.
No adverse event; The patient received vaccine past is beyond use date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (The patient received vaccine past is beyond use date) and NO ADVERSE EVENT (No adverse event) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013H21B, 014F21A, 006B21A and 004M20A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 06-Apr-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 06-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (The patient received vaccine past is beyond use date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (The patient received vaccine past is beyond use date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (The patient received vaccine past is beyond use date).    No Concomitant medications were provided.  For first and second Moderna primary series vaccine arm of administration was not known and no adverse reactions were reported.   Patient received first Moderna monovalent booster dose and had no Adverse reactions were known of.  The patient received vaccine past was beyond use date and Manufacturers expiration date.  No treatment medications were provided.
Patient started feeling nauseous and dizzy right after vaccine  was administered .  He was walked to the restroom with the assist of a staff and had 1 episode of vomiting.  He still felt nauseated. He declined to be assessed by emergency medical services.  He also complained of shakiness. His initial vital signs  were  128/78, 18 breaths per minute, 98.3 F. The final vital signs were 126/75 sitting, 120/80 standing. Breath sounds were clear bilaterally, and apical pulse was within normal limits. Patient was monitored for 30 minutes, and went home.
pt presents to pharmacy 10/23/20 complaining of 2 months of shoulder pain/limited movement in left shoulder. pt notes pain is worse at night/when lying down/performing certain motions (twisting a light switch, putting arm in pocket and pulling out). highest pain leve 7-8/10 - lasts for 10 seconds.
Congestion; Lower leg pain; Low grade fever; Cough; Shortness of breath upon exertion; Feeling poorly; Bed-bound; Activities of daily living impaired; This case was reported by a pharmacist via call center representative and described the occurrence of nasal congestion in a 34-year-old female patient who received Flu Seasonal QIV Quebec (FluLaval Tetra 2019-2020 season) (batch number 72RS4, expiry date 30th June 2020) for prophylaxis.   On 13th September 2019, the patient received FluLaval Tetra 2019-2020 season (intramuscular). In September 2019, less than a day after receiving FluLaval Tetra 2019-2020 season, the patient experienced nasal congestion, leg pain, low grade fever, cough, exertional dyspnea, feels poorly, bedridden and activities of daily living impaired. On an unknown date, the outcome of the nasal congestion, leg pain, low grade fever, cough, exertional dyspnea, feels poorly, bedridden and activities of daily living impaired were recovered/resolved.   It was unknown if the reporter considered the nasal congestion, leg pain, low grade fever, cough, exertional dyspnea, feels poorly, bedridden and activities of daily living impaired to be related to FluLaval Tetra 2019-2020 season.  Additional information received were as follows: The director of pharmacy reported that the patient received the Flulaval vaccine on an unknown deltoid. Within 24 hours after receiving Flulaval vaccine, the patient started feeling poorly with symptoms of congestion, cough, low grade fever and lower leg pain. Within 2 days after receiving Flulaval vaccine, the leg pain continued and the patient noted shortness of breath upon exertion. The patient presented at the emergency room for evaluation. The neurology consult in the the emergency room had concerned for neuropathy or myopathy and the employee was referred to outpatient neurology for follow up. The employee has been out of work on leave since this occurred and she was still bed-bound with no improvement at the time of this call. The reporter consented to follow up.  Emergency room visit required. No further details available at the time of this call. The director of pharmacy consented to follow up. This case is 1 of the 3 linked cases, reported by the same reporter.
no appetite; can't fall asleep; have a surge of adrenaline and it is very bizarre; bad headaches; cant concentrate well; sudden inexplicable panic attack; strong waves of panic and anxiety; palpitations; brain fog; forgetfulness; chills; sweating; poor apetite; elevated resting heart rate; dry heaving; higher than normal blood pressure; This is a spontaneous report from a contactable consumer or other non-HCP. A 30-years-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EP6955) via an unspecified route of administration, administered in Left Arm on 16Mar2021 12:15 as 1st dose, single for covid-19 immunization. The patient medical history and concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine and none other medications the patient received within 2 weeks of vaccination. On 04Apr2021 14:00 the patient experienced sudden inexplicable panic attack, strong waves of panic and anxiety, palpitations, brain fog, forgetfulness, chills, sweating, poor appetite, elevated resting heart rate, dry heaving and higher than normal blood pressure. On an unspecified date the patient experienced no appetite, can't fall asleep, have a surge of adrenaline and it is very bizarre, bad headaches, cant concentrate well. No treatment received for the event. The outcome of event sudden inexplicable panic attack, strong waves of panic and anxiety, palpitations, brain fog, forgetfulness, chills, sweating, poor appetite, elevated resting heart rate, dry heaving, higher than normal blood pressure was not recovered and the outcome of event no appetite, can't fall asleep, have a surge of adrenaline and it is very bizarre, bad headaches, cant concentrate well was unknown   No follow-up attempts are needed. No further information is expected
pain at the injection site / patient is still sore / gets a sharp pain which is worse at night; This case was reported by a other health professional and described the occurrence of injection site pain in a female patient who received Flu Seasonal QIV Quebec (FluLaval Tetra 2020-2021 season) (batch number Z392F, expiry date 30th June 2021) for prophylaxis.   Co-suspect products included flu seasonal qiv quebec pre-filled syringe device (Flulaval Tetra Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 16th October 2020, the patient received the 1st dose of FluLaval Tetra 2020-2021 season and Flulaval Tetra Pre-Filled Syringe Device. On 16th November 2020, 31 days after receiving FluLaval Tetra 2020-2021 season and Flulaval Tetra Pre-Filled Syringe Device, the patient experienced injection site pain. On an unknown date, the outcome of the injection site pain was unknown.   It was unknown if the reporter considered the injection site pain to be related to FluLaval Tetra 2020-2021 season and Flulaval Tetra Pre-Filled Syringe Device.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: This case was reported by office manager. The age at vaccination was not reported. The reporter stated that the patient called the office on 16th November 2020 stating where the shot was given on the right deltoid there was pain at the injection site. There was no lump, redness, swelling or rash.  On 20th November 2020, the patient was evaluated by the doctor and stated that patient was still sore and got a sharp pain which was worse at night. This case was linked wiith US2021AMR005709 and US2020AMR252174 reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR252174:same reporter US-GLAXOSMITHKLINE-US2021AMR005709:same reporter
vaccine administered at 1600; at 1630 epinephrine 0.3 mg administered x1 dose to right thigh by other provider, 1635 EMS was called, 1637 pt's husband was notified, 1647 EMS arrived, 1650 pt left clinic via wheelchair with EMS.  Pt remained awake, alert, oriented and talking normal throughout this time.
Broken bones; Fever 102.2; General weakness; Injection site pain; This is a spontaneous report from a contactable other health professional reported for himself. A 62-year-old male received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 16Feb2021 08:15 on Arm left at single dose (Lot # EL9267) for covid-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. No allergies to medications, food, or other products. He experienced Fever 102.2, broken bones, general weakness and injection site pain on 17Feb2021, which were non serious. Tylenol were received for the events. The patient had not been tested for COVID-19. Outcome of the events was recovered.; Sender's Comments: The event broken bones was considered as an intercurrent condition and unrelated to the use of BNT162B2. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.
body pain; loss of taste; stomach pains; joint pains; nausea; fatigue; pain at injection site; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (body pain), AGEUSIA (loss of taste), ABDOMINAL PAIN UPPER (stomach pains), ARTHRALGIA (joint pains) and NAUSEA (nausea) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 immunisation. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 15-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Mar-2021, the patient experienced PAIN (body pain), AGEUSIA (loss of taste), ABDOMINAL PAIN UPPER (stomach pains), ARTHRALGIA (joint pains), NAUSEA (nausea), FATIGUE (fatigue) and VACCINATION SITE PAIN (pain at injection site). At the time of the report, PAIN (body pain), AGEUSIA (loss of taste), ABDOMINAL PAIN UPPER (stomach pains), ARTHRALGIA (joint pains), NAUSEA (nausea), FATIGUE (fatigue) and VACCINATION SITE PAIN (pain at injection site) outcome was unknown.            No concomitant medications were reported.   No treatment information was provided.   This case was linked to MOD21-055337, MOD21-055429, US-MODERNATX, INC.-MOD-2021-046223 (E2B Linked Report).   Reporter did not allow further contact; Sender's Comments:  MOD21-055337: MOD21-055429: US-MODERNATX, INC.-MOD-2021-046223:patient case (male)
Rash, started on 2/14/2021 at injection site, mild to moderately pruritic, indurated, erythematous, warm to touch, approximately 3 inches x 3 inches on 2/15/2021